Trinity Biotech Plc - ADR (TRIB) gains 7.14% for July 21

Equities Staff  |

Trinity Biotech Plc - ADR (NASDAQ: TRIB) shares gained 7.14%, or $0.13 per share, to close Wednesday at $1.95. After opening the day at $1.84, shares of Trinity fluctuated between $2.04 and $1.75. 719,473 shares traded hands an increase from their 30 day average of 188,519. Wednesday's activity brought Trinity’s market cap to $40,758,321.

Trinity is headquartered in Bray, Wicklow..

About Trinity Biotech Plc - ADR

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Visit Trinity Biotech Plc - ADR’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Trinity Biotech Plc - ADR and to follow the company’s latest updates, you can visit the company’s profile page here: Trinity Biotech Plc - ADR’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content